Inactive Instrument

Otsuka Holdings Co., Ltd. Share Price Other OTC

Equities

OTSKY

US6891641010

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 2,168B 14.02B 1,170B Sales 2025 * 2,153B 13.92B 1,161B Capitalization 3,507B 22.67B 1,892B
Net income 2024 * 254B 1.65B 137B Net income 2025 * 233B 1.51B 126B EV / Sales 2024 * 1.39 x
Net cash position 2024 * 496B 3.21B 268B Net cash position 2025 * 635B 4.1B 343B EV / Sales 2025 * 1.33 x
P/E ratio 2024 *
13.7 x
P/E ratio 2025 *
14.7 x
Employees -
Yield 2024 *
1.86%
Yield 2025 *
1.93%
Free-Float 81.41%
More Fundamentals * Assessed data
Dynamic Chart
Otsuka Holdings' Attributable Profit Jumps 26% in Q1 MT
Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation MT
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Lowers 2023 Profit Outlook MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range RE
Japan's Nikkei soars to 34-year high on chip shares, earnings RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint MT
More news
Managers TitleAgeSince
Chief Executive Officer 73 08/08/08
Director of Finance/CFO 62 01/15/01
Chairman 59 08/08/08
Members of the board TitleAgeSince
Chief Executive Officer 73 08/08/08
Chairman 59 08/08/08
Director/Board Member 57 30/17/30
More insiders
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW